+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Atrial Fibrillation - Pipeline Review, H1 2020

  • ID: 4997729
  • Drug Pipelines
  • February 2020
  • Region: Global
  • 127 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Acesion Pharma Aps
  • ARCA biopharma Inc
  • Daiichi Sankyo Co Ltd
  • Gilead Sciences Inc
  • Nissan Chemical Corp
  • Rhythm Therapeutics Inc
  • MORE
Atrial Fibrillation - Pipeline Review, H1 2020

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Atrial Fibrillation - Pipeline Review, H1 2020, provides an overview of the Atrial Fibrillation (Cardiovascular) pipeline landscape.

Atrial fibrillation is an irregular and often rapid heart rate that commonly causes poor blood flow to the body. Symptoms include decreased blood pressure, weakness, lightheadedness, confusion and chest pain. The predisposing factors include age, heart disease, high blood pressure, family history and drinking alcohol. Treatments for atrial fibrillation may include medications and surgery.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Atrial Fibrillation - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Atrial Fibrillation (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Atrial Fibrillation (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Atrial Fibrillation and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 3, 7, 5, 10, 2 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Atrial Fibrillation (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Atrial Fibrillation (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Atrial Fibrillation (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Atrial Fibrillation (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Atrial Fibrillation (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Atrial Fibrillation (Cardiovascular)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Atrial Fibrillation (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Atrial Fibrillation (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Acesion Pharma Aps
  • ARCA biopharma Inc
  • Daiichi Sankyo Co Ltd
  • Gilead Sciences Inc
  • Nissan Chemical Corp
  • Rhythm Therapeutics Inc
  • MORE
Introduction
Atrial Fibrillation - Overview
Atrial Fibrillation - Therapeutics Development
Atrial Fibrillation - Therapeutics Assessment
Atrial Fibrillation - Companies Involved in Therapeutics Development
Atrial Fibrillation - Drug Profiles
Atrial Fibrillation - Dormant Projects
Atrial Fibrillation - Discontinued Products
Atrial Fibrillation - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Atrial Fibrillation, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Atrial Fibrillation - Pipeline by Acesion Pharma Aps, H1 2020
Atrial Fibrillation - Pipeline by Allergan Plc, H1 2020
Atrial Fibrillation - Pipeline by Allosteros Therapeutics Inc, H1 2020
Atrial Fibrillation - Pipeline by AnaBios Corp, H1 2020
Atrial Fibrillation - Pipeline by ARCA biopharma Inc, H1 2020
Atrial Fibrillation - Pipeline by Armaron Bio Pty Ltd, H1 2020
Atrial Fibrillation - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2020
Atrial Fibrillation - Pipeline by Correvio Pharma Corp, H1 2020
Atrial Fibrillation - Pipeline by Daiichi Sankyo Co Ltd, H1 2020
Atrial Fibrillation - Pipeline by Espero BioPharma Inc, H1 2020
Atrial Fibrillation - Pipeline by G3 Pharmaceuticals Inc, H1 2020
Atrial Fibrillation - Pipeline by Gilead Sciences Inc, H1 2020
Atrial Fibrillation - Pipeline by HUYA Bioscience International LLC, H1 2020
Atrial Fibrillation - Pipeline by Hyloris Pharmaceuticals SA, H1 2020
Atrial Fibrillation - Pipeline by InCarda Therapeutics Inc, H1 2020
Atrial Fibrillation - Pipeline by Merck & Co Inc, H1 2020
Atrial Fibrillation - Pipeline by Merz Pharma GmbH & Co KgaA, H1 2020
Atrial Fibrillation - Pipeline by Milestone Pharmaceuticals Inc, H1 2020
Atrial Fibrillation - Pipeline by Nissan Chemical Corp, H1 2020
Atrial Fibrillation - Pipeline by Novartis AG, H1 2020
Atrial Fibrillation - Pipeline by OMEICOS Therapeutics GmbH, H1 2020
Atrial Fibrillation - Pipeline by Rhythm Therapeutics Inc, H1 2020
Atrial Fibrillation - Pipeline by Rithim Biologics Inc, H1 2020
Atrial Fibrillation - Pipeline by The Geneva Biotech Center SA, H1 2020
Atrial Fibrillation - Pipeline by Toa Eiyo Ltd, H1 2020
Atrial Fibrillation - Pipeline by Verseon Corp, H1 2020
Atrial Fibrillation - Pipeline by Vivasc Therapeutics Inc, H1 2020
Atrial Fibrillation - Dormant Projects, H1 2020
Atrial Fibrillation - Dormant Projects, H1 2020 (Contd..1), H1 2020
Atrial Fibrillation - Dormant Projects, H1 2020 (Contd..2), H1 2020
Atrial Fibrillation - Discontinued Products, H1 2020
Atrial Fibrillation - Discontinued Products, H1 2020 (Contd..1), H1 2020

List of Figures
Number of Products under Development for Atrial Fibrillation, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Acesion Pharma Aps
  • Allergan Plc
  • Allosteros Therapeutics Inc
  • AnaBios Corp
  • ARCA biopharma Inc
  • Armaron Bio Pty Ltd
  • Chong Kun Dang Pharmaceutical Corp
  • Correvio Pharma Corp
  • Daiichi Sankyo Co Ltd
  • Espero BioPharma Inc
  • G3 Pharmaceuticals Inc
  • Gilead Sciences Inc
  • HUYA Bioscience International LLC
  • Hyloris Pharmaceuticals SA
  • InCarda Therapeutics Inc
  • Merck & Co Inc
  • Merz Pharma GmbH & Co KgaA
  • Milestone Pharmaceuticals Inc
  • Nissan Chemical Corp
  • Novartis AG
  • OMEICOS Therapeutics GmbH
  • Rhythm Therapeutics Inc
  • Rithim Biologics Inc
  • The Geneva Biotech Center SA
  • Toa Eiyo Ltd
  • Verseon Corp
  • Vivasc Therapeutics Inc
Note: Product cover images may vary from those shown
Adroll
adroll